Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research
February 22, 2024
SALT LAKE CITY, UT, February 22, 2024 (BusinessWire) – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development. With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony brings extensive knowledge and expertise to Seek Labs where she will spearhead the pharmaceutical research division, leading strategic initiatives to advance Seek Labs’ innovation in novel gene therapies.
An immunologist and cell biologist by training, O’Mahony has extensive experience leading scientific teams and assay operations in drug discovery. She has led academic research efforts, CRO-based phenotypic screening services, and drug discovery efforts in biotech. O’Mahony has served as a subject-matter expert in disease biology (immunology, inflammation, immune-oncology, and fibrosis), has published several peer-reviewed articles, and presented at international conferences.
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS